# Beijing Joy Orient Translational Medicine Research Center

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-joy-orient-translational-medicine-research-center

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.deyidongfang.com
- Total disclosed funding: $14M
- Latest round: Series A (Dec 14, 2016)
- Investors on record: 2

## About

Beijing Joy Orient Translational Medicine Research Center focuses on advancing translational medicine research, providing innovative solutions and technologies that bridge the gap between scientific discoveries and clinical applications in healthcare.Established in 2012, Beijing Joy Orient Translational Medicine Research Center is dedicated to the research and development of translational medicine. The company has undergone no significant pivots in strategy since its inception. The firm is located in Beijing, China, and was founded by Weiyue Gu, who has a background in healthcare research. In December 2016, the company raised CNY 100 million in a Series A round led by Fortune Capital and Fosun PingYao Investment & Management, bringing the total amount raised to CNY 100 million.Beijing Joy Orient specializes in translational medicine research, focusing on developing innovative diagnostic and therapeutic solutions. Their services include research collaborations, clinical trial consulting, and the development of new biomedical technologies aimed at improving patient outcomes in various medical fields.The company generates revenue primarily through research contracts, collaborations with healthcare institutions, and consulting services related to clinical trials and medical research. Their pricing strategy reflects the quality and depth of their research capabilities, catering to a diverse client base in the healthcare sector.Beijing Joy Orient Translational Medicine Research Center plans to enhance its research capabilities by developing new diagnostic tools and therapies, with several new products set to launch by late 2024. The company aims to expand its operations into international markets, specifically targeting North America and Europe by 2025. The recent funding round in December 2016 will be utilized to support these initiatives, enhancing research infrastructure and expanding market reach.

## Funding rounds

- Series A, Dec 14, 2016, $14M — Fortune Capital, Fosun PingYao Investment & Management

## Investors

- Fortune Capital — Series A
- Fosun PingYao Investment & Management — Series A